iPS-abgeleitete Kardiomyozyten als therapeutische Hoffnungsträger

Abstract

AbstractAfter ischemic injury in adolescence, the human heart has only limited capacity to regenerate. The loss of cardiomyocytes is typically replaced by fibrotic scar tissue. The resulting scars reduce myocardial contractility and function. To date, the gold standard for end-stage heart disease remains a heart transplant, which is not a realistic option due to donor heart shortage. The regenerative potential of reprogrammed stem cells has the potential for a long-expected breakthrough in development of efficient therapeutic interventions.